John M. Levenick, MD, from the Penn State Hershey Medical Center, and colleagues conducted a prospective trial of 449 patients undergoing ECRP. Patients were randomized to a single dose of rectal indomethacin or a placebo suppository.
Here are three points:
1. The researchers found between 7.2 percent and 4.9 percent of patients in the indomethacin and placebo groups, respectively, developed pancreatitis.
2. Between the groups, complications and pancreatitis’ severity were similar.
3. The study was stopped early owing to futility per a priori protocol guidelines.
More articles on GI & endoscopy:
Gastroenterologist to know: Dr. Steven Abo of the University of Pittsburgh
Depression, somatization linked to postprandial symptoms in IBS patients — 5 points
Researchers find differences in colonoscopy quality — 4 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
